Insider Buying Update for Wednesday, December 17: SRRK, ADGM

Written by Emily J. Thompson, Senior Investment Analyst

SRRK+4.52%

ADGM+2%

Source: NASDAQ.COM

Updated: Dec 17 2025

0mins

Source: NASDAQ.COM

Insider Purchase at Scholar Rock: Srinivas Akkaraju bought 29,599 shares of Scholar Rock Holding (SRRK) for $1.18M at $39.92 each, seeing a 13.5% gain during the trading session.
Previous Investment by Akkaraju: Prior to this purchase, Akkaraju had acquired $18.81M worth of shares at $37.58 each within the last year.
Adagio Medical Holdings CEO Purchase: Todd Usen, CEO of Adagio Medical Holdings, purchased 207,315 shares for $225,973 at $1.09 each, while the stock was down about 2.5% on the day.
Market Performance: Scholar Rock Holding's stock was up approximately 0.4% on Wednesday, with SRRK reaching a high of $45.32 during trading.

Discover Tomorrow's Bullish Stocks Today

Receive free daily stock recommendations and professional analysis to optimize your portfolio's potential.

SRRK

$45.08+Infinity%1D

Analyst Views on SRRK

Wall Street analysts forecast SRRK stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SRRK is 50.00 USD with a low forecast of 42.00 USD and a high forecast of 60.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

11 Analyst Rating

11 Buy

0 Hold

0 Sell

Strong Buy

Current: 43.130

Low

42.00

Averages

50.00

High

60.00

Current: 43.130

Low

42.00

Averages

50.00

High

60.00

H.C. Wainwright

Andres Maldonado

Buy

maintain

$44 -> $58

2026-01-26

New

Reason

H.C. Wainwright

Andres Maldonado

Price Target

$44 -> $58

AI Analysis

2026-01-26

New

maintain

Buy

Reason

H.C. Wainwright analyst Andres Maldonado raised the firm's price target on Scholar Rock to $58 from $44 and keeps a Buy rating on the shares. The firm has increased confidence in apitegromab's launch trajectory following key opinion leader feedback. Physicians consistently highlighted that additional FDA interactions and greater clarity around manufacturing remediation have reduced uncertainty, with several noting that Scholar Rock's parallel supply chain strategy meaningfully de-risks early launch execution, the analyst tells investors in a research note.

Citi

NULL -> Buy

initiated

$55

2026-01-09

Reason

Citi

Price Target

$55

2026-01-09

initiated

NULL -> Buy

Reason

Citi initiated coverage of Scholar Rock with a Buy rating and $55 price target. The firm believes concerns over the company's manufacturing on apitegromab in spinal muscular atrophy are overdone. Citi's checks indicate a near-term resolution of the manufacturing issues and potential application resubmission approval by Q1 of 2026.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for SRRK

Unlock Now

About SRRK

Scholar Rock Holding Corporation is a late-stage biopharmaceutical company. It is focused on advancing treatments for neuromuscular diseases, cardiometabolic disorders, and other serious diseases. Its transforming growth factor beta (TGFb) superfamily biology, its novel molecular mechanisms of growth factor activation enabled it to develop a proprietary platform for the discovery and development of monoclonal antibodies that locally and selectively target the precursor, or latent, forms of growth factors. Its product candidate, apitegromab, is a selective, fully human, monoclonal antibody, with a mechanism of action that results in inhibition of the activation of the growth factor, myostatin, in skeletal muscle. Apitegromab is being developed as a potential first muscle-targeted therapy for the treatment of SMA. Its products include SRK-439, SRK-181, SRK-373 and SRK-256. SRK-181 is a selective inhibitor of the activation of latent TGFb1, is being developed for the treatment of cancers.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

GET FREE REAL TIME NOTIFICATIONS

Stock Monitor for SRRK?

Get Started Free

FREE STOCK RECOMMENDATIONS DAILY

Stock Bullish Tomorrow

Get Started Free

70% BACKTESTED ACCURACY!

Should I Buy SRRK?

Get Started Free

Top News

Scholar Rock Grants 35,200 Shares in Inducement Awards to New Hires

Jan 16 2026Newsfilter

Inducement Awards: Scholar Rock granted a total of 35,200 shares of common stock to two new employees, comprising 20,400 shares in stock options and 14,800 shares in restricted stock units, aimed at attracting top talent to the company.
Option Exercise Price: The granted stock options have an exercise price of $43.56 per share, matching the closing price of Scholar Rock's common stock on January 12, 2026, ensuring that new hires' interests are closely aligned with the company's stock performance.
Vesting Schedule: 25% of the stock options will vest on the first anniversary of each employee's start date, with the remaining 75% vesting in 12 equal quarterly installments, while the restricted stock units will vest in four equal annual installments, ensuring ongoing employee commitment to the company.
Plan Background: This grant is made under the company's inducement equity plan adopted on June 16, 2022, designed to attract individuals who were not previously employed by Scholar Rock, in compliance with Nasdaq listing rules.